Bolt Biotherapeutics has been granted a patent for a Dectin-2 binding agent, which includes specific immunoglobulin heavy and light chain variable region polypeptides. The invention also covers methods for treating diseases in mammals and stimulating antigen presenting cells. GlobalData’s report on Bolt Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bolt Biotherapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Bolt Biotherapeutics's grant share as of September 2023 was 6%. Grant share is based on the ratio of number of grants to total number of patents.
Dectin-2 binding agent for treating diseases in mammals
A recently granted patent (Publication Number: US11753474B2) discloses a Dectin-2 binding agent that can enhance immune responses and treat diseases in mammals. The binding agent consists of an immunoglobulin heavy chain variable region polypeptide and an immunoglobulin light chain variable region polypeptide. The immunoglobulin heavy chain variable region polypeptide includes specific complementarity determining regions (CDRs) with corresponding sequences, while the immunoglobulin light chain variable region polypeptide also includes specific CDRs with corresponding sequences.
The patent claims cover various aspects of the Dectin-2 binding agent. Claim 1 describes the binding agent with specific CDR sequences, while claim 2 describes the binding agent with different specific CDR sequences. Claim 3 specifies that the amino acid sequences of the binding agent must be at least 90% identical to certain reference sequences. Claim 4 describes the binding agent with specific amino acid sequences.
Claims 5 to 41 describe the binding agent as an antibody or antibody fragment, with various modifications and characteristics. Claims 42 to 49 describe the binding agent as part of a multispecific or bispecific antibody or other antibody-based constructs.
Claims 50 to 59 describe specific characteristics of the binding agent as an IgG antibody, including mutations in the Fc region that modulate binding to Fc receptors. Claims 60 to 70 describe methods of enhancing immune responses and treating diseases by administering the binding agent to mammals with specific types of cancer.
Claims 71 to 95 describe methods of stimulating antigen presenting cells (APCs) in mammals with specific types of cancer by contacting the APCs with the binding agent. Claims 96 to 105 describe methods of enhancing immune responses and treating diseases by administering the binding agent to mammals with specific types of cancer.
Claims 106 to 131 describe methods of stimulating APCs in mammals with specific types of cancer by contacting the APCs with the binding agent.
Overall, this patent provides a detailed description of a Dectin-2 binding agent and its potential applications in enhancing immune responses and treating various types of cancer. The patent covers different variations and modifications of the binding agent, as well as methods of using it in therapeutic settings.
To know more about GlobalData’s detailed insights on Bolt Biotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
